Actavis PLC (ACT): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Actavis ( ACT) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 1.1%. By the end of trading, Actavis fell $4.20 (-2.3%) to $181.80 on average volume. Throughout the day, 1,889,387 shares of Actavis exchanged hands as compared to its average daily volume of 1,272,200 shares. The stock ranged in price between $181.28-$186.34 after having opened the day at $186.00 as compared to the previous trading day's close of $186.00. Other companies within the Drugs industry that declined today were: Pain Therapeutics ( PTIE), down 14.3%, Oramed Pharmaceuticals ( ORMP), down 13.1%, iBio ( IBIO), down 11.2% and Rexahn Pharmaceuticals ( RNN), down 10.3%.

Actavis plc, an integrated specialty pharmaceutical company, develops, manufactures, markets, and distributes pharmaceutical products in the United States, Canada, and internationally. Actavis has a market cap of $31.6 billion and is part of the health care sector. Shares are up 10.7% year to date as of the close of trading on Tuesday. Currently there are 11 analysts that rate Actavis a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Actavis as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity.

On the positive front, Chelsea Therapeutics International ( CHTP), up 91.7%, Agios Pharmaceuticals ( AGIO), up 18.6%, Kindred Biosciences ( KIN), up 16.0% and Amarin Corporation ( AMRN), up 15.9% , were all gainers within the drugs industry with GlaxoSmithKline ( GSK) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

Stocks Trade Mixed, Energy Shares Fall on Sharp Drop in Oil Prices

Stocks Trade Mixed, Energy Shares Fall on Sharp Drop in Oil Prices

Video: You Could Live in a Ritz-Carlton or St. Regis Home

Video: You Could Live in a Ritz-Carlton or St. Regis Home

Component Stocks Rise After Trump Reverses Decision on ZTE

Component Stocks Rise After Trump Reverses Decision on ZTE

Crude Slides as Russia Eases Cuts and U.S. Oil Producers Boost Rig Count

Crude Slides as Russia Eases Cuts and U.S. Oil Producers Boost Rig Count

Best Buy's Billionaire Founder: We Were 'Late to the Game' in Online Shopping

Best Buy's Billionaire Founder: We Were 'Late to the Game' in Online Shopping